HRTX

Business Context and Reporting Period

Company: A.P. Pharma, Inc. (Note: Metadata listed "Heron Therapeutics," but the filing text identifies the registrant as A.P. Pharma, Inc.)
Period: Quarterly Report (Form 10-Q) for the three months ended March 31, 2009.
Business Overview: A specialty pharmaceutical company focused on developing products using proprietary Biochronomer polymer-based drug delivery technology. The primary focus is the lead product candidate, APF530, for the prevention of chemotherapy-induced nausea and vomiting (CINV). A pivotal Phase III trial was completed in 2008, and the company expects to submit a New Drug Application (NDA) to the FDA in the second quarter of 2009. Development of other pipeline products has been deferred to focus resources on APF530.

Key Financial Metrics

Liquidity: As of March 31, 2009, the company held $7.5 million in cash, cash equivalents, and marketable securities. Management believes this is sufficient to fund operations into the fourth quarter of 2009.

Material Changes vs. Prior Period

• Revenue: Contract revenue decreased significantly from $133,000 in Q1 2008 to $8,000 in Q1 2009 due to variable activity levels under collaborative arrangements.
• Operating Expenses: Total operating expenses dropped by approximately 59% to $2.98 million.
  • R&D: Decreased by $4.09 million (to $2.05 million) primarily due to the completion of the APF530 Phase III trial and a reduction in force in November 2008.
  • G&A: Decreased by $153,000 (to $927,000) due to cost containment and lower stock-based compensation.
• Net Loss: Improved significantly to a loss of $2.96 million compared to $6.84 million in the prior year period.
• Cash Flow: Net cash used in operating activities decreased to $3.07 million from $6.99 million in the prior year. Net cash provided by investing activities turned positive ($217,000) due to maturities of marketable securities exceeding purchases of property and equipment.

Outlook, Risks, and Management Commentary

• Going Concern: The financial statements are prepared assuming the company will continue as a going concern. However, the company has incurred significant operating losses and has an accumulated deficit of $134 million. Management is seeking additional financing, which may include a collaborative arrangement or equity offering. Failure to secure financing could require further reduction of activities or discontinuation of operations.
• Strategic Focus: All corporate resources are focused on the APF530 NDA submission (expected Q2 2009) and negotiations for a commercialization partnership. Other pipeline products are on hold.
• Investments: Due to the financial crisis, 95% of available cash is invested in a money market fund containing U.S. Government-backed securities. Asset-backed securities held showed an unrealized loss of $21,000, assessed as temporary.
• Contingencies: A liability of $621,000 is accrued for "Gross Profit Guarantees" related to the sale of the cosmeceutical business. The company has not paid amounts asserted by the successor company (Amcol) pending documentation of actual costs.

Investor Verification Checklist

• Financing Status: Verify if the company has secured the additional financing required to fund operations beyond Q4 2009.
• APF530 NDA Submission: Confirm the timing and status of the New Drug Application submission to the FDA.
• Commercialization Partnership: Monitor progress on negotiations for a commercialization partner for APF530.
• Discontinued Operations Liability: Review the status of the $621,000 accrued liability regarding the Gross Profit Guaranty with Amcol.
• Stock-Based Compensation: Note the significant number of outstanding stock options (3.55 million) which could be dilutive upon exercise.